drugset / Trial / NCT05993884
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke
Phase 1
Completed
27 enrolled
Allife Medical Science and Technology Co., Ltd.
Beijing Tiantan Hospital · collabLinfen Central Hospital · collabLinyi People's Hospital · collabPeking University Third Hospital · collabXuanwu Hospital, Beijing · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-Escalation clinical study to investigate the safety and efficacy of EPCs transplantation in Acute ischemic stroke.
Timeline
- Start
- 2023-08-24
- Primary completion
- 2025-04-15
- Completion
- 2025-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iEPCs | Cell therapy | — | Intravenous |